Pfizer has announced the availability of attention deficit hyperactivity disorder (ADHD) therapy, Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension, in the US.
The extended-release liquid methylphenidate is indicated for the treatment of ADHD in patients from six years of age by administering once a day.
Pfizer emerging markets and established products business units, medical and development, senior vice president Sam Azoulay said the compny is providing the patients suffering from the challenging condition with a new treatment option.
"We also recognize that caring for and treating a child with ADHD goes beyond medication," Azoulay added.
A randomized, double-blind, placebo-controlled, crossover, laboratory classroom study conducted in 45 children with ADHD has established the efficacy profile of Quillivant XR.
The central nervous system stimulant prescription medicine improved ADHD symptoms compared to placebo at the primary endpoint of four hours post-dose.
Secondary analysis finds significant improvement at each time point measured, from 45 minutes to 12 hours following dosing.
